New cholesterol drug inclisiran tracked in belgian heart patients
NCT ID NCT05726838
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 600 Belgian adults with atherosclerotic cardiovascular disease who are prescribed inclisiran, a cholesterol-lowering injection, alongside their usual medications. Researchers will measure how much LDL cholesterol drops and how many patients reach their target levels in real-life conditions. The goal is to see if inclisiran works as well outside clinical trials as it does in them.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Inclisiran (a cholesterol-lowering injection)
What this could lead to
If successful, this study could confirm that inclisiran works well in everyday practice to help heart disease patients reach their LDL cholesterol goals.
What could go wrong
This is an observational registry, not a controlled trial, so results may be influenced by patient selection or other factors. It does not test a new treatment, only monitors existing use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.